Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
The European psychiatric association (EPA) – early career psychiatristscommittee survey on trainees’ and early-career psychiatrists’ attitudestowards therapeutic drug monitoring (TDM) use and utility duringantipsychotic treatment. / Schoretsanitis, Georgios; Correll, Christoph U.; Agorastos, Agorastos; Compaired Sanchez, Alejandro ; Erzin, Gamze; Grigoras, Ruxandra M.; Benussi, Mateja Grizelj; Gondek, Tomasz; Guloksuz, Sinan; Højlund, Mikkel; Jerotic, Stefan; Kilic, Ozge; Metaj, Enita; Singh Sidhu, Deshwinder ; Skandali, Nikolina; Skuhareuski, Aliaksei; Tveito, Marit; Wolthusen, Rick P. F.; Чумаков, Егор Максимович; de Filippis, Renato.
в: World Journal of Biological Psychiatry, 21.06.2024.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - The European psychiatric association (EPA) – early career psychiatristscommittee survey on trainees’ and early-career psychiatrists’ attitudestowards therapeutic drug monitoring (TDM) use and utility duringantipsychotic treatment
AU - Schoretsanitis, Georgios
AU - Correll, Christoph U.
AU - Agorastos, Agorastos
AU - Compaired Sanchez, Alejandro
AU - Erzin, Gamze
AU - Grigoras, Ruxandra M.
AU - Benussi, Mateja Grizelj
AU - Gondek, Tomasz
AU - Guloksuz, Sinan
AU - Højlund, Mikkel
AU - Jerotic, Stefan
AU - Kilic, Ozge
AU - Metaj, Enita
AU - Singh Sidhu, Deshwinder
AU - Skandali, Nikolina
AU - Skuhareuski, Aliaksei
AU - Tveito, Marit
AU - Wolthusen, Rick P. F.
AU - Чумаков, Егор Максимович
AU - de Filippis, Renato
PY - 2024/6/21
Y1 - 2024/6/21
N2 - Objectives: This survey assessed psychiatry residents’/early-career psychiatrists’ attitudes towards the utility of therapeutic drug monitoring (TDM) of antipsychotics. Methods: A previously developed questionnaire on attitudes on TDM utility during antipsychotic treatment was cross-sectionally disseminated by national coordinators between 01/01/2022–31/12/2023. The frequency of using TDM for antipsychotics other than clozapine was the main outcome in a linear regression analysis, including sex, clinical setting, caseload, and factors generated by an exploratory factor analysis. Comparisons between residents and early-career psychiatrists, respondents working in in- and outpatient settings, and low-/middle- and high–income countries were performed. Results: Altogether, 1,237 respondents completed the survey, with 37.9% having never used TDM for antipsychotics. Seven factors explained 41% of response variance; six of them were associated with frequency of TDM use (p < 0.05). Items with highest loadings for factors included clinical benefits of TDM (factors A and E: 0.7), negative expectations for beliefs of patients towards TDM (factor B: 0.6–0.7), weak TDM scientific evidence (factor C: 0.8), and TDM availability (factor D: −0.8). Respondents from low-/middle-income countries were less likely to frequently/almost always use TDM compared to high-income countries (9.4% vs. 21.5%, p < 0.001). Discussion: TDM use for antipsychotics was poor and associated with limited knowledge and insufficient availability.
AB - Objectives: This survey assessed psychiatry residents’/early-career psychiatrists’ attitudes towards the utility of therapeutic drug monitoring (TDM) of antipsychotics. Methods: A previously developed questionnaire on attitudes on TDM utility during antipsychotic treatment was cross-sectionally disseminated by national coordinators between 01/01/2022–31/12/2023. The frequency of using TDM for antipsychotics other than clozapine was the main outcome in a linear regression analysis, including sex, clinical setting, caseload, and factors generated by an exploratory factor analysis. Comparisons between residents and early-career psychiatrists, respondents working in in- and outpatient settings, and low-/middle- and high–income countries were performed. Results: Altogether, 1,237 respondents completed the survey, with 37.9% having never used TDM for antipsychotics. Seven factors explained 41% of response variance; six of them were associated with frequency of TDM use (p < 0.05). Items with highest loadings for factors included clinical benefits of TDM (factors A and E: 0.7), negative expectations for beliefs of patients towards TDM (factor B: 0.6–0.7), weak TDM scientific evidence (factor C: 0.8), and TDM availability (factor D: −0.8). Respondents from low-/middle-income countries were less likely to frequently/almost always use TDM compared to high-income countries (9.4% vs. 21.5%, p < 0.001). Discussion: TDM use for antipsychotics was poor and associated with limited knowledge and insufficient availability.
KW - Early career psychiatrists (ECPs)
KW - personalised medicine
KW - psychopharmacology
KW - schizophrenia
KW - therapeutic drug monitoring (TDM)
UR - https://www.mendeley.com/catalogue/c79aca9d-a25a-3848-84a4-23d7ca17b5ca/
U2 - 10.1080/15622975.2024.2367138
DO - 10.1080/15622975.2024.2367138
M3 - Article
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
SN - 1562-2975
ER -
ID: 121116503